Thus, we recommend the re-evaluation of LIG4 as a candidate for targeted radiosensitization of GBM as soon as inhibitors with improved pharmacological profile are available in order to clarify if LIG4 is mechanistically involved in GBM radioresistance or if the correlation of its expression levels with inherent radioresistance has no causal implications. This evidence concerns the gene LIG4 and glioblastoma.